Daniel Rea

Has grant

Professor of Medical Oncology

University of Birmingham

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Medical Imaging Medical Imaging professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Daniel Rea is a faculty member in the Department of Medical Oncology at the University of Birmingham, UK. His research focuses on breast cancer treatment strategies, including the optimization of endocrine therapies and the evaluation of morphometric signatures for ductal carcinoma in situ. Professor Rea's recent publications address critical areas such as the use of deep learning in mammography assessments and the implications of chemotherapy regimens for early-stage breast cancer survivors.

Recent Grants

Grant: Close

ROSCO RDA

Open Date: 2019-01-01

Close Date:

Grant: Close

transattom

Open Date: 2016-06-01

Close Date:

Grant: Close

Nostra Feasability

Open Date: 2016-01-01

Close Date: 2026-01-01

Grant: Close

ROSCO

Open Date: 2013-03-01

Close Date:

Grant: Close

ROSCO

Open Date: 2013-03-01

Close Date:

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (19)

Benjamin H. Mullish

UNITED KINGDOM

Daniel Rea

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.

A morphometric signature to identify ductal carcinoma in situ with a low risk of progression.

Conquering Overtreatment of DCIS: Lessons from PRECISION.

Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.

DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Recruiting women with Ductal Carcinoma In Situ to a randomised controlled trial: lessons from the LORIS study

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: Multinational, pooled cohort study

Collaborators (19)

Benjamin H. Mullish

Sally Wheelwright

Jeremy Braybrooke

Helena Earl

Pericles Foroglou

Terry Hyslop

Donal Skelly

Stefan Siebert

Barbara Kronsteiner-Dobramysl

Valerie Jenkins

Malcolm Reed

Stephen P. McAdoo

Luis Teixeira

Sean Hua Lim

Anthony Brown

Lesley Fallowfield

Madelon Voets

seamus o'reilly

Eleanor Barnes

Make your next move.